Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Prediction of marbling score and carcass traits in Korean Hanwoo beef cattle using machine learning methods and synthetic minority oversampling technique.

Shahinfar S, Al-Mamun HA, Park B, Kim S, Gondro C.

Meat Sci. 2020 Mar;161:107997. doi: 10.1016/j.meatsci.2019.107997. Epub 2019 Nov 12.

PMID:
31812939
2.

Use of Medicinal Plants and Synthetic Medicines by Pregnant Women in Kerman, Iran.

Saber M, Khanjani N, Zamanian M, Safinejad H, Shahinfar S, Borhani M.

Arch Iran Med. 2019 Jul 1;22(7):390-393.

3.

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.

Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA.

Pediatr Nephrol. 2019 Apr;34(4):739-740. doi: 10.1007/s00467-018-4154-5.

4.

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.

Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, Laskin B, Shahinfar S, Vande Walle J, Schaefer F.

Pediatr Nephrol. 2019 Mar;34(3):475-486. doi: 10.1007/s00467-018-4116-y. Epub 2018 Nov 30.

PMID:
30506144
5.

An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.

Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA.

Pediatr Nephrol. 2019 Jan;34(1):145-154. doi: 10.1007/s00467-018-4054-8. Epub 2018 Aug 23. Erratum in: Pediatr Nephrol. 2019 Apr;34(4):739-740.

6.

Optimization of reproductive management programs using lift chart analysis and cost-sensitive evaluation of classification errors.

Shahinfar S, Guenther JN, Page CD, Kalantari AS, Cabrera VE, Fricke PM, Weigel KA.

J Dairy Sci. 2015 Jun;98(6):3717-28. doi: 10.3168/jds.2014-8255. Epub 2015 Apr 1.

7.

A randomized, open-label, dose-response study of losartan in hypertensive children.

Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, Santoro EP, McCrary Sisk C, Blaustein RO.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1441-8. doi: 10.2215/CJN.11111113. Epub 2014 May 29.

8.

Short communication: Prediction of retention pay-off using a machine learning algorithm.

Shahinfar S, Kalantari AS, Cabrera V, Weigel K.

J Dairy Sci. 2014 May;97(5):2949-52. doi: 10.3168/jds.2013-7373. Epub 2014 Feb 26.

9.

Prediction of insemination outcomes in Holstein dairy cattle using alternative machine learning algorithms.

Shahinfar S, Page D, Guenther J, Cabrera V, Fricke P, Weigel K.

J Dairy Sci. 2014 Feb;97(2):731-42. doi: 10.3168/jds.2013-6693. Epub 2013 Dec 2.

10.

Creatinine excretion rate and mortality in type 2 diabetes and nephropathy.

Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, Navis G, Lambers Heerspink HJ.

Diabetes Care. 2013 Jun;36(6):1489-94. doi: 10.2337/dc12-1545. Epub 2013 Jan 8.

11.

Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.

Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.

Pediatr Nephrol. 2013 May;28(5):737-43. doi: 10.1007/s00467-012-2372-9. Epub 2012 Dec 4.

PMID:
23207876
12.

Revival of classical vortex generators now for transition delay.

Shahinfar S, Sattarzadeh SS, Fransson JH, Talamelli A.

Phys Rev Lett. 2012 Aug 17;109(7):074501. Epub 2012 Aug 16.

PMID:
23006373
13.

Prediction of breeding values for dairy cattle using artificial neural networks and neuro-fuzzy systems.

Shahinfar S, Mehrabani-Yeganeh H, Lucas C, Kalhor A, Kazemian M, Weigel KA.

Comput Math Methods Med. 2012;2012:127130. Epub 2012 Sep 9.

14.

Losartan and enalapril are comparable in reducing proteinuria in children.

Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.

Kidney Int. 2012 Oct;82(7):819-26. doi: 10.1038/ki.2012.210. Epub 2012 Jun 27.

15.

Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.

Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ.

Am J Kidney Dis. 2012 Jan;59(1):75-83. doi: 10.1053/j.ajkd.2011.09.017. Epub 2011 Nov 3.

PMID:
22051245
16.

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ.

Hypertension. 2011 Jul;58(1):2-7. doi: 10.1161/HYPERTENSIONAHA.111.171488. Epub 2011 May 31.

PMID:
21632472
17.

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ.

Kidney Int. 2011 Aug;80(3):282-7. doi: 10.1038/ki.2011.79. Epub 2011 Mar 30.

18.

Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.

Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, Le Bailly De Tilleghem C.

Nephrol Dial Transplant. 2011 Aug;26(8):2521-6. doi: 10.1093/ndt/gfq797. Epub 2011 Feb 1.

PMID:
21285125
19.

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, Shahinfar S, Grobbee D, de Zeeuw D.

Diabetologia. 2011 Jan;54(1):44-50. doi: 10.1007/s00125-010-1922-6. Epub 2010 Sep 30. Erratum in: Diabetologia. 2011 Aug;54(8):2209.

20.

Comparison of different measures of urinary protein excretion for prediction of renal events.

Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, de Zeeuw D.

J Am Soc Nephrol. 2010 Aug;21(8):1355-60. doi: 10.1681/ASN.2010010063. Epub 2010 Jul 15.

21.

Randomized, double-blind, controlled study of losartan in children with proteinuria.

Webb NJ, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, Santoro E, Manas D, Gleim GW.

Clin J Am Soc Nephrol. 2010 Mar;5(3):417-24. doi: 10.2215/CJN.06620909. Epub 2010 Jan 14.

22.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM.

J Am Soc Nephrol. 2008 Apr;19(4):771-9. doi: 10.1681/ASN.2007050582. Epub 2008 Jan 16.

23.

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.

Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD.

Kidney Int. 2008 Mar;73(5):630-6. Epub 2007 Dec 19.

24.

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.

PMID:
18070995
25.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators.

Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17.

26.

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.

J Am Soc Nephrol. 2007 May;18(5):1540-6. Epub 2007 Apr 4.

27.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D.

J Hypertens. 2007 Apr;25(4):871-6.

PMID:
17351381
28.

A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension.

Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, Blumer JL, Vogt BA, Lo MW, Hand E, Panebianco D, Rippley R, Shaw W, Shahinfar S.

Pediatr Nephrol. 2007 May;22(5):695-701. Epub 2007 Jan 10.

PMID:
17216247
30.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

Clin Exp Nephrol. 2006 Sep;10(3):193-200.

PMID:
17009077
31.

Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.

Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.

Diabetes Care. 2006 Oct;29(10):2210-7.

PMID:
17003295
32.

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

Pharmacoeconomics. 2006;24(6):549-58.

PMID:
16761903
33.

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.

Kidney Int. 2006 May;69(9):1675-82.

34.

Losartan: lessons learned from the RENAAL study.

Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM.

Expert Opin Pharmacother. 2006 Apr;7(5):623-30. Review.

PMID:
16553578
35.

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.

Am J Cardiol. 2005 Dec 1;96(11):1530-6. Epub 2005 Oct 17.

PMID:
16310435
36.

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving HH; RENAAL Investigators.

Diabetologia. 2005 Oct;48(10):1980-7. Epub 2005 Aug 5.

PMID:
16082528
37.

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.

J Am Soc Nephrol. 2005 Jun;16(6):1775-80. Epub 2005 May 4.

38.

Losartan and end-organ protection--lessons from the RENAAL study.

Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators.

Clin Cardiol. 2005 Mar;28(3):136-42.

39.

A double-blind, dose-response study of losartan in hypertensive children.

Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, Gleim G, Miller K, Vogt B, Blumer J, Briazgounov I.

Am J Hypertens. 2005 Feb;18(2 Pt 1):183-90. Erratum in: Am J Hypertens. 2006 Jun;19(6):658.

PMID:
15752945
40.

Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.

Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM; RENAAL Investigators.

Kidney Int Suppl. 2005 Jan;(93):S48-51. Review. No abstract available.

PMID:
15663528
41.

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM; RENAAL Study Group.

J Am Soc Nephrol. 2004 Dec;15(12):3117-25.

42.

Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular disease.

Mitch WE, Shahinfar S, Dickson TZ, de Zeeuw D, Zhang Z.

Kidney Int Suppl. 2004 Nov;(92):S97-8. Review.

43.

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.

Kidney Int Suppl. 2004 Nov;(92):S115-7. Review.

44.

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD.

Kidney Int. 2004 Sep;66(3):1131-8.

45.

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Circulation. 2004 Aug 24;110(8):921-7. Epub 2004 Aug 9.

PMID:
15302780
46.

The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy.

Leung WY, So WY, Tong PC, Lo MK, Lee KF, Ko GT, Chan WB, Cockram CS, Brenner BM, Shahinfar S, Critchley JA, Chan JC.

Nephrol Dial Transplant. 2004 Oct;19(10):2519-25. Epub 2004 Jul 27.

PMID:
15280527
47.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.

48.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.

Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Asian RENAAL Study Investigators.

Diabetes Care. 2004 Apr;27(4):874-9.

PMID:
15047641
49.

A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension.

Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S.

Am J Hypertens. 2003 Oct;16(10):795-800.

PMID:
14553956
50.

The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.

Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, De Zeeuw D, Kamper AL, Strangaard S, Levey AS.

Nephrol Dial Transplant. 2003 Oct;18(10):2047-53.

PMID:
13679479

Supplemental Content

Loading ...
Support Center